Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

By LabMedica International staff writers
Posted on 17 Nov 2026

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive impairment and dementia can develop over many years, longer-term risk estimates may provide more meaningful clinical context. Blood-based biomarkers could offer a less invasive way to support this type of risk assessment.

Researchers at Mayo Clinic evaluated phosphorylated tau 217 (p-tau217), a blood-based biomarker of Alzheimer’s disease, as part of a model to estimate future cognitive impairment risk in adults without symptoms. The approach combines p-tau217 levels with age, sex, and genetic risk to predict the likelihood of developing mild cognitive impairment or dementia. Higher p-tau217 concentrations and older age were associated with increased risk.


Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

The study included 1,644 cognitively unimpaired participants from the Mayo Clinic Study of Aging and 534 from the Alzheimer’s Disease Neuroimaging Initiative. Participants were aged 60 to 90 and underwent blood p-tau217 testing, genetic assessment, and repeated cognitive evaluations. Researchers used Mayo Clinic data to develop five- and 10-year risk estimates, then confirmed the association between elevated p-tau217 levels and cognitive decline in the independent cohort.

For example, a 75-year-old woman without the APOE ε4 genetic risk variant had an estimated five-year risk of mild cognitive impairment of 5% with low p-tau217 levels, increasing to 16% with higher levels. Her estimated 10-year risk rose from 12% to 35%. At the same elevated p-tau217 level, five-year risk estimates also varied substantially by age, ranging from 6% at age 65 to 37% at age 85.

Published in JAMA Neurology on November 16, 2026, the findings build on earlier Mayo Clinic research using amyloid positron emission tomography (PET) imaging to predict cognitive impairment. Although the blood-based approach could support more individualized risk assessment, researchers emphasized the need for validation in more diverse populations and with other p-tau217 assays. Alzheimer’s biomarker testing is not currently recommended for individuals without cognitive symptoms.

“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” said Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher and first author of the study.

“Absolute risk gives the biomarker result clinical context. If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment,” said Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist and senior author of the study.

Related Links
Mayo Clinic


Latest Clinical Chem. News